Clearside Biomedical (CLSD)
(Delayed Data from NSDQ)
$3.76 USD
-0.13 (-3.34%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $3.81 +0.05 (1.33%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Fundamental Charts
About Return on Equity (TTM)
Clearside Biomedical, Inc.'s return on equity, or ROE, is -533.87% compared to the ROE of the Medical - Biomedical and Genetics industry of -63.65%. While this shows that CLSD has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
CLSD 3.76 -0.13(-3.34%)
Will CLSD be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CLSD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CLSD
Clearside Biomedical, Inc. (CLSD) Reports Q2 Loss, Beats Revenue Estimates
Compugen (CGEN) Reports Q2 Loss, Lags Revenue Estimates
CLSD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Clearside Biomedical (CLSD) Upgraded to Buy: Here's What You Should Know
Clearside Biomedical, Inc. (CLSD) Reports Q1 Loss, Tops Revenue Estimates
Lineage Cell (LCTX) Reports Q1 Loss, Lags Revenue Estimates
Other News for CLSD
Is CLSD about to break its pattern? NR7 shows up after sliding 3.34%
Is CLSD positioned for a breakdown? Slingshot Bearish shows up after soaring 7.76%
Is CLSD ready to move lower? New 52 Week Low shows up after gaining 1.12%
CLSD makes New 52 Week Closing Low on September 16
CLSD makes New 52 Week Closing Low on September 15